Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02787369
Title ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Idelalisib + Ricolinostat

Ibrutinib + Ricolinostat

Age Groups: adult
Covered Countries USA


No variant requirements are available.